Detail akcie Biogen Idec online

Business Summary: Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Biogen Inc revenues decreased 3% to $9.84B. Net income decreased 62% to $1.16B. Revenues reflect Rest of World segment decrease of 9% to $4.11B, United States segment decrease of 9% to $3.14B. Net income also reflects G/L on Invest HFS, Maturity & Trading decrease from $1.51B (income) to $0K, Gain on sale of building decrease from $503.7M (income) to $0K.